Biofrontera Inc. Warrants (BFRIW)
Stock · NASDAQ · Health Care
$0.0052as of 10/15/2026
Price chart
Active signals
High Beta63.1%
Resistance level
$0.020668
Industry
Biotechnology: Pharmaceutical Preparations
About BFRIW
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massac…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 84
Fundamentals
- 1-day range
- $0.0052$0.006
- Market cap
- $357.2K
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 2.42
- Avg. volume
- —
52-week range
$0.0052$0.1484
Biofrontera Inc. Warrants Competitors
Chosen by industry and closest market cap.
- BFRIWBiofrontera Inc. Warrants$0.0052▼ 7.14%Market cap $357.2KP/E —$0.0052$0.1484
- CINGWCingulate Inc. Warrants$0.01▲ 14.94%Market cap $133.3KP/E —$0.0026$0.12
- ERNAWErnexa Therapeutics Inc. Warrants$0.0253▼ 9.96%Market cap $52.4KP/E —$0.0213$0.2278
- CDTTWCDT Equity Inc. Warrant$0.0074▲ 21.31%Market cap $9.3KP/E —$0.002$0.02
- BIVIWBioVie Inc. Warrant$0.2301▼ 7.96%Market cap $1.06MP/E —$0.13$0.79
- BDRXBiodexa Pharmaceuticals plc American Depositary Shs$0.456▲ 5.80%Market cap $1.10MP/E —$0.3371$44.7
- MTNBMatinas Biopharma Holdings Inc. Common Stock$2.37▼ 2.07%Market cap $1.72MP/E —$2.26$28.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BFRIW Biofrontera Inc. Warrants | $357.2K | — | $0.0052 | ▼ 7.14% | $0.0052$0.1484 |
| CINGW Cingulate Inc. Warrants | $133.3K | — | $0.01 | ▲ 14.94% | $0.0026$0.12 |
| ERNAW Ernexa Therapeutics Inc. Warrants | $52.4K | — | $0.0253 | ▼ 9.96% | $0.0213$0.2278 |
| CDTTW CDT Equity Inc. Warrant | $9.3K | — | $0.0074 | ▲ 21.31% | $0.002$0.02 |
| BIVIW BioVie Inc. Warrant | $1.06M | — | $0.2301 | ▼ 7.96% | $0.13$0.79 |
| BDRX Biodexa Pharmaceuticals plc American Depositary Shs | $1.10M | — | $0.456 | ▲ 5.80% | $0.3371$44.7 |
| MTNB Matinas Biopharma Holdings Inc. Common Stock | $1.72M | — | $2.37 | ▼ 2.07% | $2.26$28.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Institutional Ownership
March 31, 2026
- Total shares held
- 212.2K
- Total value held
- $8.2K
- Institutional holders
- 6
Top holders this quarter
- Unknown154.9K
- Unknown45.8K
- Unknown9.0K
- Unknown1.1K
- Unknown1.0K
- Unknown343
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Biofrontera Files Supplemental NDA to Expand Ameluz® Use
Biofrontera has submitted a supplemental new drug application to the FDA to broaden the use of its Ameluz® Red Light Photodynamic Therapy to treat actinic keratoses on the full body. The filing is a regulatory step that could enlarge the drug’s potential market if the new indication is approved. It shows the company is actively pursuing additional uses to support future growth.
Biofrontera Files Supplemental NDA to Expand Ameluz® Use. Biofrontera has submitted a supplemental new drug application to the FDA to broaden the use of its Ameluz® Red Light Photodynamic Therapy to treat actinic keratoses on the full body. The filing is a regulatory step that could enlarge the drug’s potential market if the new indication is approved. It shows the company is actively pursuing additional uses to support future growth.